Solute carrier family 34 member 2 overexpression contributes to tumor growth and poor patient survival in colorectal cancer.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

• Publication date

  2018-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.biopha.2018.01.124PMID 29653487
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SLC34A2 Regulates the Proliferation, Migration, and Invasion of Human Osteosarcoma Cells Through PTEN/PI3K/AKT Signaling

  2017cited by this paper
• Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway

  2017cited by this paper
• Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b

  2017cited by this paper
• Overexpression of SLC34A2 is an independent prognostic indicator in bladder cancer and its depletion suppresses tumor growth via decreasing c-Myc expression and transcriptional activity

  2017cited by this paper
• Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.

  2017cited by this paper
• Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer

  2017cited by this paper
• Intrinsic gene changes determine the successful establishment of stable renal cancer cell lines from tumor tissue

  2017cited by this paper
• Cell-Cycle Therapeutics Come of Age.

  2017cited by this paper
• Cancer statistics, 2017

  2017cited by this paper
• Colorectal cancer statistics, 2017

  2017cited by this paper
• T-cell leukemia/lymphoma-1A predicts the clinical outcome for patients with stage II/III colorectal cancer.

  2017cited by this paper
• Elevated NDC80 expression is associated with poor prognosis in osteosarcoma patients.

  2017cited by this paper
• High expression of SLC34A2 is a favorable prognostic marker in lung adenocarcinoma patients

  2017cited by this paper
• A novel SLC34A2 mutation in a patient with pulmonary alveolar microlithiasis

  2017cited by this paper
• Knockdown of SLC34A2 Inhibits Hepatocellular Carcinoma Cell Proliferation and Invasion.

  2016cited by this paper
• The effects and mechanisms of SLC34A2 on tumorigenicity in human non-small cell lung cancer stem cells

  2016cited by this paper
• High expression of Zinc-finger protein X-linked promotes tumor growth and predicts a poor outcome for stage II/III colorectal cancer patients

  2016cited by this paper
• Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling

  2016cited by this paper
• MicroRNA-410 acts as oncogene in NSCLC through downregulating SLC34A2 via activating Wnt/β-catenin pathway

  2016cited by this paper
• Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality.

  2016cited by this paper
• Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer.

  2016cited by this paper
• The Role of Sodium-Dependent Phosphate Transporter in Phosphate Homeostasis.

  2015cited by this paper
• The sodium-phosphate co-transporter SLC34A2, and pulmonary alveolar microlithiasis: Presentation of an inbred family and a novel truncating mutation in exon 3

  2015cited by this paper
• The effects and mechanisms of SLC34A2 in tumorigenesis and progression of human non-small cell lung cancer

  2015cited by this paper
• Biological effects of inorganic phosphate: potential signal of toxicity.

  2015cited by this paper
• Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200

  2015cited by this paper
• Global cancer statistics, 2012

  2015cited by this paper
• Elevated expression of SLC34A2 inhibits the viability and invasion of A549 cells

  2014cited by this paper
• The SLC34 family of sodium-dependent phosphate transporters

  2013cited by this paper
• Rebmab200, a Humanized Monoclonal Antibody Targeting the Sodium Phosphate Transporter NaPi2b Displays Strong Immune Mediated Cytotoxicity against Cancer: A Novel Reagent for Targeted Antibody Therapy of Cancer

  2013cited by this paper
• Immunohistochemical analysis of NaPi2b protein (MX35 antigen) expression and subcellular localization in human normal and cancer tissues.

  2011cited by this paper
• Predictive and Prognostic Factors in Colorectal Cancer: A Personalized Approach

  2011cited by this paper
• SLC34A2 as a novel marker for diagnosis and targeted therapy of breast cancer.

  2010cited by this paper
• Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas.

  2008cited by this paper
• ORIGINAL ARTICLE DOI: 10.3904/kjim.2010.25.4.399 Microarray Analysis of Papillary Thyroid Cancers in Korean

  year unknowncited by this paper

• Analysis of gene co-expression and protein–protein interaction networks involving the sodium-dependent phosphate transporter NaPi2b in ovarian normal and tumor tissues

  2026cites this paper
• The Solute Carrier (SLC) Transporter Superfamily as Therapeutic Targets for the Treatment of Ovarian Serous Cystadenocarcinoma.

  2026cites this paper
• Carcinogenesis Associated with Toxin Nephropathy: Proposed Mediation by Phosphate Toxicity

  2025cites this paper
• T330M Substitution in the Sodium-Dependent Phosphate Transporter NaPi2b Abolishes the Efficacy of Monoclonal Antibodies Against MX35 Epitope

  2025cites this paper
• SLC34A2 promotes cell proliferation by activating STX17‐mediated autophagy in esophageal squamous cell carcinoma

  2024cites this paper
• Sodium-dependent phosphate transporter NaPi2b as a candidate for targeted therapy: features of structure, function, and expression

  2024cites this paper
• Toward a Topology-Based Therapeutic Design of Membrane Proteins: Validation of NaPi2b Topology in Live Ovarian Cancer Cells

  2022cites this paper
• Identification of the Antigens Recognised by Colorectal Cancer Patients Using Sera from Patients Who Exhibit a Crohn’s-like Lymphoid Reaction

  2022cites this paper
• Recognition of mutant forms of the sodium-dependent phosphate transporter NaPi2b by ­monoclonal antibodies in ovarian cancer cells

  2022cites this paper
• SLC34A2 promotes cancer proliferation and cell cycle progression by targeting TMPRSS3 in colorectal cancer.

  2021cites this paper
• Evaluation of the Prognostic Value of Solute Carrier Family 34 Member 2 “SLC34A2” in Papillary Thyroid Carcinoma: An Immunohistochemical Study

  2021cites this paper
• Identification of Potential BRAF Inhibitor Joint Therapy Targets in PTC based on WGCAN and DCGA

  2021cites this paper
• SLC34A2 Up-regulation And SLC4A4 Down-regulation Correlates With Invasion, Metastasis, And The MAPK Signaling Pathway In Papillary Thyroid Carcinomas

  2021cites this paper
• Characterization of SLC34A2 as a Potential Prognostic Marker of Oncological Diseases

  2021cites this paper
• Modulating phosphate consumption, a novel therapeutic approach for the control of cancer cell proliferation and tumorigenesis.

  2020cites this paper
• Recognition of the Sodium-Dependent Phosphate Transporter NaPi2b by Monoclonal Antibodies N-NaPi2b in Ovarian Cancer Cells

  2020cites this paper
• Phosphate Transport in Epithelial and Nonepithelial Tissue.

  2020cites this paper
• Patent Highlights February-March 2018.

  2018cites this paper
• NaPi- II b as a potential diagnostic and prognostic biomarker in ovarian cancers

  2018cites this paper
• NaPi-Ⅱ b as a potential diagnostic and prognostic biomarker in ovarian cancers

  year unknowncites this paper